OQROGet OQRO Pro
Insider trade

Idexx Laboratories (IDXX)CEO sold ~$765K

Jonathan Jay Mazelsky, CEO at Idexx Laboratories, sold ~$765K of Idexx Laboratories shares.

~$765K
Approx. value · 1,171 sh @ $653.68
102K
Holds after · shares reported
Traded
Feb 26, 2026
Filed
Mar 2, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 2, 2025CongressDisclosed partial sale of IDXX — reported range $1,001 - $15,000
  2. Jan 11, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On January 11, 2026, Jonathan (Jay) Mazelsky notified IDEXX Laboratories, Inc. (the “Company” or “IDEXX”) of his intent to step down as the Company’s President and Chief Executive Officer effective as of May 12, 2026 (the “Transition Date”) and retire from the Company and the Company’s Board of the Directors (the “Board”) immediately following the Company’s annual meeting of shareholders in May 2027 (the “Retirement…”
  3. Jan 13, 2026CongressDisclosed sale of IDXX — reported range $1,001 - $15,000
  4. Feb 2, 2026Company filing · Form 8-K · ResultsReported its results
  5. Feb 10, 2026Insider · 1 personInsiders: 8 sales (~$7.3M)
  6. Feb 13, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 13, 2026, Ms. M. Anne Szostak provided IDEXX Laboratories, Inc. (the “Company”) notice of her intention to retire from the Board of Directors (the “Board”) effective immediately following the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) to be held on May 12, 2026.”
  7. Feb 17, 2026Insider · 2 peopleInsiders: 8 sales (~$4.3M)
  8. Feb 26, 2026 · this disclosureInsiderCEO sold ~$765K of IDXX shares in the open market

What came next

  1. Feb 26, 2026Insider · 2 peopleInsiders: 13 sales (~$16.4M)
  2. Mar 3, 2026Insider · Named in an 8-K 21 days laterOfficer sold ~$1.12M of IDXX shares in the open market
  3. Mar 24, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 24, 2026, IDEXX Laboratories, Inc. (“IDEXX”) and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on April 13, 2026 (the “Separation Date”) and will continue to provide advisory services on an as-needed basis until July 13, 2026 (the “Final Employment Date”).”
  4. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  5. Apr 30, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  6. May 5, 2026Company filing · Form 8-K · ResultsReported its results
  7. May 12, 2026Company filing · Form 8-K · Bylaws or charter, Shareholder voteChanged its bylaws, charter or fiscal year, and held a shareholder vote
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Idexx Laboratories

For Idexx Laboratories, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 30 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IDXX page.

Other recent filings by Jonathan Jay Mazelsky, President and CEO

The full history of Jonathan Jay Mazelsky, President and CEO is on the profile page.

How this filing works

Other disclosures at Idexx Laboratories

Everything OQRO holds on this company is on its IDXX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data